Linked Life Data

16842133

Source:http://linkedlifedata.com/resource/pubmed/id/16842133

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2006-7-17
pubmed:abstractText
It is known that the renin-angiotensin system (RAS) plays a fundamental role not only as a vasoconstrictor in controlling blood pressure and electrolyte/fluid homeostasis, but also as a mitogenic factor through the Ang-II type-1 (AT1) receptor in smooth muscle cells and cardiac myocytes. Angiotensin II (Ang-II) is indeed thought to be a growth factor, and Ang-II receptor blockers (ARBs), a class of antihypertensive agent, suppress signal transduction pathways mediated by several growth factors or cytokines, through the AT1 receptor. There is increasing evidence that the RAS is implicated in the development of various cancers. We previously demonstrated that ARBs have the potential to inhibit the growth of prostate cancer cells and tumors through the AT1 receptor. This review highlights the possibility of ARBs as novel agents for prostate cancer as well as other cancers, and reviews the literature on this area.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1389-5575
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
835-44
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
Angiotensin II receptor blocker: possibility of antitumor agent for prostate cancer.
pubmed:affiliation
Department of Urology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Yokohama 236-0004, Japan. hu0428@med.yokohama-cu.ac.jp
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't